Home/Pipeline/HLCM051 (MultiStem)

HLCM051 (MultiStem)

Acute Respiratory Distress Syndrome (ARDS)

Phase 2/3Completed ONE-BRIDGE trial in Japan; Fast Track/RMAT designated

Key Facts

Indication

Acute Respiratory Distress Syndrome (ARDS)

Phase

Phase 2/3

Status

Completed ONE-BRIDGE trial in Japan; Fast Track/RMAT designated

Company

Healios, Healios

About Healios

Healios develops iPSC-based regenerative therapies for ophthalmology, ARDS, and oncology, aiming to deliver cures for intractable diseases.

View full company profile

About Healios

Healios develops iPSC-based regenerative therapies for ophthalmology, ARDS, and oncology, aiming to deliver cures for intractable diseases.

View full company profile

Therapeutic Areas

Ophthalmology Pulmonology Oncology Neurology

Other Acute Respiratory Distress Syndrome (ARDS) Drugs

Drug	Company	Phase	Status
MultiStem	Athersys	Phase 3	Active (subject to funding)
BXT-25	BioXyTran	Preclinical	Active
Bioengineered Surfactant Program	BioSuperior	Pre-clinical	Active
FX06	F4 Pharma	Phase 1/2	Active
AVM0703	AVM Biotechnology	Pre-clinical / Research	Active
ACE2v2-Fc	Cyrus Biotechnology	Preclinical	Active
GEn-1124	GEn1E Lifesciences	Phase 2	Active
AZM-152	Azome Therapeutics	Pre-clinical	Active
Zelpultide Alfa	Airway Therapeutics	Pre-clinical/Research	Active
ALT-100 mAb	Aqualung Therapeutics	Phase 2a	Active
RP-323	PhorMed	Phase 2	Active
Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS	Sedana Medical	Investigator-Initiated Trial	Active